Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Exelixis, Inc. (NASDAQ: EXEL).

Full DD Report for EXEL

You must become a subscriber to view this report.

Recent News from (NASDAQ: EXEL)

Cabometyx approved in Europe for first-line kidney cancer; Exelixis up 5% premarket
Exelixis (NASDAQ: EXEL ) is up  5%  premarket, albeit on only 100 shares, in response to its announcement that the European Commission has approved commercialization partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application for CABOMETYX (cabozantinib) for the first-li...
Source: SeekingAlpha
Date: May, 17 2018 07:20
NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback
We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger NewLink Genetics (NASDAQ: NLNK...
Source: SeekingAlpha
Date: May, 17 2018 05:16
Exelixis' Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
– Approval based on statistically significant and clinically meaningful improvement in progression-free survival for CABOMETYX versus sunitinib in CABOSUN trial – – Triggers $50 million milestone payment to Exelixis under licensing agreement with Ipsen – ...
Source: Business Wire
Date: May, 17 2018 01:01
Reader Inquiry: Will Core Biotech Holding Exelixis Rebound?
Shares of emerging oncology star Exelixis ( EXEL ) have risen by an astounding 500% over the past three years. However, the stock finished slightly in the red over the past twelve months. While the stock is up 75% since I called it a ¨compelling buy¨ in late 2016, as a member of...
Source: SeekingAlpha
Date: May, 16 2018 05:28
Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Lucky Seven: Achaogen Likely To Bounce Back
The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C...
Source: SeekingAlpha
Date: May, 14 2018 08:19
Exelixis Will Continue It's Stride Despite Cotellic Combo Failure In Colorectal Cancer
Recently, Exelixis ( EXEL ) and its partner Roche ( RHHBY ) announced that the phase 3 study treating patients with colorectal cancer did not succeed . It was announced that the combination of Cotellic with Tecentriq failed to improve overall survival ((OS)) in this patient population. ...
Source: SeekingAlpha
Date: May, 14 2018 01:53
Exelixis: Time To Excel
Exelixis (EXEL) has seen a very difficult 2018 so far, after the company has seen a very impressive momentum run in 2016 and 2017 following strong clinical results for CABOMETYX, approval of this drug and a good start to sales in the first quarters following launch. Earlier this year, I lo...
Source: SeekingAlpha
Date: May, 13 2018 20:56
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop
Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all...
Source: SeekingAlpha
Date: May, 12 2018 00:23


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EXEL.

About Exelixis, Inc. (NASDAQ: EXEL)

Logo for Exelixis, Inc. (NASDAQ: EXEL)

Not available


Contact Information



Current Management

  • George A. Scangos / President, CEO
  • Glen Y. Sato / CFO

Current Share Structure

  • Market Cap: $6,059,042,816 - 05/16/2018
  • Issue and Outstanding: 296,866,380 - 04/23/2018


Recent Filings from (NASDAQ: EXEL)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 05 2018



Daily Technical Chart for (NASDAQ: EXEL)

Daily Technical Chart for (NASDAQ: EXEL)

Stay tuned for daily updates and more on (NASDAQ: EXEL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EXEL)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EXEL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EXEL and does not buy, sell, or trade any shares of EXEL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: